The Key To Big Pharma Deals: How Korea's ABL Reached $1bn Sanofi Agreement

Science, Data Form Backbone

ABL Bio CEO shares experience from reaching a $1bn licensing deal with Sanofi, why it chose the French giant as its partner, what happened during the negotiation process and the next steps for the Korean company.

Sang Hoon Lee, ABL Bio CEO
ABL Bio CEO Sang Hoon Lee Talks Around Ambitions To Set New Role Model For Korean Biotechs • Source: ABL Bio

“I have a background as a scientist although I am serving a different role now as the CEO. I feel very proud to have shown a good case of solid science leading to business,” stated Sang Hoon Lee, CEO and founder of ABL Bio Inc., which reached a major global out-licensing deal with Sanofi in January.

The potential $1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia